Recombinant Antibody Microarray for Profiling the Serum Proteome of SLE

  • Carl A. K. Borrebaeck
  • Gunnar Sturfelt
  • Christer Wingren
Part of the Methods in Molecular Biology book series (MIMB, volume 1134)


Systemic lupus erythematosus (SLE) is a severe autoimmune connective tissue disease. Our current knowledge about the serum proteome, or serum biomarker panels, reflecting disease and disease status is still very limited. Affinity proteomics, represented by recombinant antibody arrays, is a novel, multiplex technology for high-throughput protein expression profiling of crude serum proteomes in a highly specific, sensitive, and miniaturized manner. The antibodies are deposited one by one in an ordered pattern, an array, onto a solid support. Next, the sample is added, and any specifically bound proteins are detected and quantified. The binding pattern is then converted into a relative protein expression map, or protein map, deciphering the composition of the sample at the molecular level. The methodology provides unique opportunities for delineating serum biomarkers reflecting SLE, thus paving the way for improved diagnosis, classification, and prognosis.


Antibody microarray Protein expression profiling SLE Biomarkers Diagnosis Prognosis Classification 



This work was supported by grants from the Swedish National Science Council (VR-NT and VR-M), the SSF Strategic Center for Translational Cancer Research (CREATE Health), and Vinnova.


  1. 1.
    Rahman A, Isenberg DA (2008) Systemic lupus erythematosus. N Engl J Med 358:929–939PubMedCrossRefGoogle Scholar
  2. 2.
    D’Cruz DP, Khamashta MA, Hughes GR (2007) Systemic lupus erythematosus. Lancet 369:587–596PubMedCrossRefGoogle Scholar
  3. 3.
    Liu CC, Ahearn JM (2009) The search for lupus biomarkers. Best Pract Res 23:507–523CrossRefGoogle Scholar
  4. 4.
    Rovin BH, Zhang X (2009) Biomarkers for lupus nephritis: the quest continues. Clin J Am Soc Nephrol 4:1858–1865PubMedCrossRefGoogle Scholar
  5. 5.
    Hanash S (2003) Disease proteomics. Nature 422:226–232PubMedCrossRefGoogle Scholar
  6. 6.
    Borrebaeck CAK, Wingren C (2009) Design of high-density antibody microarrays for disease proteomics: key technological issues. J Proteomics 72:928–935PubMedCrossRefGoogle Scholar
  7. 7.
    Haab BB (2006) Applications of antibody array platforms. Curr Opin Biotechnol 17:415–421PubMedCrossRefGoogle Scholar
  8. 8.
    Kingsmore SF (2006) Multiplexed protein measurement: technologies and applications of protein and antibody arrays. Nat Rev 5:310–320Google Scholar
  9. 9.
    Sanchez-Carbayo M (2011) Antibody microarrays as tools for biomarker discovery. Methods Mol Biol 785:159–182PubMedCrossRefGoogle Scholar
  10. 10.
    Wingren C, Borrebaeck CAK (2006) Antibody microarrays: current status and key technological advances. OMICS 10:411–427PubMedCrossRefGoogle Scholar
  11. 11.
    Wingren C, Borrebaeck CAK (2007) Progress in miniaturization of protein arrays—a step closer to high-density nanoarrays. Drug Discov Today 12:813–819PubMedCrossRefGoogle Scholar
  12. 12.
    Wingren C, Borrebaeck CAK (2009) Antibody-based microarrays. Methods Mol Biol 509:57–84PubMedCrossRefGoogle Scholar
  13. 13.
    Bauer JW, Baechler EC, Petri M, Batliwalla FM, Crawford D, Ortmann WA, Espe KJ, Li W, Patel DD, Gregersen PK, Behrens TW (2006) Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 3:e491PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Carlsson A, Wuttge DM, Ingvarsson J, Bengtsson AA, Sturfelt G, Borrebaeck CAK, Wingren C (2011) Serum protein profiling of systemic lupus erythematosus and systemic sclerosis using recombinant antibody microarrays. Mol Cell Proteomics 10(M110):005033PubMedGoogle Scholar
  15. 15.
    Wingren C, Borrebaeck CAK (2008) Antibody microarray analysis of directly labelled complex proteomes. Curr Opin Biotechnol 19:55–61PubMedCrossRefGoogle Scholar
  16. 16.
    Borrebaeck CAK, Wingren C (2007) High-throughput proteomics using antibody microarrays: an update. Expert Rev Mol Diagn 7:673–686PubMedCrossRefGoogle Scholar
  17. 17.
    Borrebaeck CAK, Wingren C (2009) Transferring proteomic discoveries into clinical practice. Expert Rev Proteomics 6:11–13PubMedCrossRefGoogle Scholar
  18. 18.
    Borrebaeck CAK, Wingren C (2011) Recombinant antibodies for the generation of antibody arrays. Methods Mol Biol 785:247–262PubMedCrossRefGoogle Scholar
  19. 19.
    Soderlind E, Strandberg L, Jirholt P, Kobayashi N, Alexeiva V, Aberg AM, Nilsson A, Jansson B, Ohlin M, Wingren C, Danielsson L, Carlsson R, Borrebaeck CA (2000) Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries. Nat Biotechnol 18:852–856PubMedCrossRefGoogle Scholar
  20. 20.
    Haab BB, Dunham MJ, Brown PO (2001) Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions. Genome Biol 2:RESEARCH0004PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Carlsson A, Wingren C, Kristensson M, Rose C, Ferno M, Olsson H, Jernstrom H, Ek S, Gustavsson E, Ingvar C, Ohlsson M, Peterson C, Borrebaeck CAK (2011) Molecular serum portraits in patients with primary breast cancer predict the development of distant metastases. Proc Natl Acad Sci U S A 108:14252–14257PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Sandstrom A, Andersson R, Segersvard R, Lohr M, Borrebaeck CAK, Wingren C (2012) Serum proteome profiling of pancreatitis using recombinant antibody microarrays reveals disease-associated biomarker signatures. Proteomics Clin Appl 6:486–496PubMedCrossRefGoogle Scholar
  23. 23.
    Wingren C, Ingvarsson J, Dexlin L, Szul D, Borrebaeck CAK (2007) Design of recombinant antibody microarrays for complex proteome analysis: choice of sample labeling-tag and solid support. Proteomics 7:3055–3065PubMedCrossRefGoogle Scholar
  24. 24.
    Ingvarsson J, Larsson A, Sjoholm AG, Truedsson L, Jansson B, Borrebaeck CAK, Wingren C (2007) Design of recombinant antibody microarrays for serum protein profiling: targeting of complement proteins. J Proteome Res 6:3527–3536PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, New York 2014

Authors and Affiliations

  • Carl A. K. Borrebaeck
    • 1
  • Gunnar Sturfelt
    • 2
  • Christer Wingren
    • 1
  1. 1.Department of Immunotechnology and CREATE HealthLund UniversityLundSweden
  2. 2.Section of Rheumatology, Department of Clinical SciencesSkånes University Hospital, Lund UniversityLundSweden

Personalised recommendations